Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Immunovia to present at Gilmartin Group’s Emerging Growth Company Showcase

LUND, SWEDEN – Immunovia today announced it will participate in Gilmartin Group's Emerging Growth Company Showcase on August 31, 2022.   Philipp Mathieu, CEO and President, and Jeff Borcherding, US CEO, are scheduled to present on Wednesday, August 31, 2022 at 9:00 am ET (15:00 pm CET).   A live and archived webcast will be available on the “Investors” section of the Immunovia website at https://investor.immunovia.com/.   For more information, please contact:Karin Almqvist LiwendahlCFOkarin.almqvist.liwendahl@immunovia.com+46 70 911 56 08  About Immunovia

Saga Pure ASA: Invitation to presentation of Q2 2022 results on 25 August 2022 at 12:00 (CEST)

In connection with the release of the results for Q2 2022, Saga Pure ASA invites to the following event: Thursday 25 May 2022 at 12.00 CET Live webcast of the company Q2 Report and Q&A. The presentation will be held at Haakon VIIs gate 2, Oslo. The Q2 Report and Presentation will be available at www.sagapure.com and by a stock exchange release from Saga Pure ASA 25 August 2022. All others are welcome follow the Q2 presentation live on webcast. Link to webcast: https://channel.royalcast.com/landingpage/hegnarmedia/20220825_9/ ENDS For additional information, please

Medivir to present at the Erik Penser Bank Company Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Erik Penser Bank Company Day on August 24, 2022. CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox).The presentation will be available after the meeting on Medivirs website; www.medivir.com.For additional information, please contactMagnus Christensen, CFO, Medivir ABTelephone: +46 8 5468 3100E-mail: magnus.christensen@medivir.comMedivir in briefMedivir develops innovative drugs with a focus

Etteplan is planning for a rights offering of approximately 110–125 million euros

Etteplan Oyj, Stock exchange release, Inside information, August 23, 2022 at 09:30 a.m. EEST Etteplan is planning for a rights offering of approximately 110–125 million euros NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Etteplan Oyj (the ”Company”) commences preparations for a rights offering of approximately 110–125 million euros. The subscription period for the offering is expected

The subscription period in Clinical Laserthermia Systems AB’s (publ) rights issue begins today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, OR CANADA OR ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. Lund, Sweden – Today, 23 August 2022, is the first day of the subscription period in Clinical Laserthermia Systems AB’s (publ), (”CLS” or the “Company”) issue of units, with preferential right for existing shareholders (the “Rights Issue”). The public is also invited to subscribe

FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer

Copenhagen, Denmark 23 August2022– FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has submitted a CTA to initiate a phase II trial in head and neck cancer. The clinical trial will be conducted at Rigshospitalet in Denmark.Following approval from the Danish Medicines Agency, FluoGuide will initiate the phase II trial in collaboration with Department of Otolaryngology, Head & Neck Surgery and Audiology at the University Hospital, Rigshospitalet, in Denmark. Principal investigator is Anders Christensen, MD, Ph.D. The phase IIa trial is designed to

DecideAct signs with Hope Aero – Canada’s leading aircraft component maintenance specialist

The Danish software company DecideAct, which offers a SaaS solution that helps companies with Strategy Execution Management, has signed a contract with the Canadian company Hope Aero, Canada's leading specialist in the maintenance of aircraft components. The agreement includes both an expert service to help clarify the strategic priorities and DecideAct's infrastructure to implement the strategy.Hope Aero is a key player in maintaining aircraft safety focusing on propeller, wheel and brake repair and overhaul, dynamic balancing, and NDT (Non-destructive testing). Within this field, Hope

Nordea cancels repurchased shares

Nordea Bank AbpStock exchange release – Total number of voting rights and capital23 August 2022 at 9.15 EET Nordea has today cancelled 17,520,108 treasury shares in line with the decision by the Board of Directors. The shares were held for capital optimisation purposes and acquired through share buy-backs. The cancellation brings the total number of shares in Nordea to 3,735,542,696. The total number of votes attached to the shares is 3,735,542,696. The cancellation of the shares was registered with the Finnish Trade Register on 23 August 2022. The company holds 2,927,860

Interim report April – June 2022

Second quarter in brief · Net sales amounted to 18.7 million SEK (11.8), which means a sales growth of 59 percent. · Operating profit amounted to 4.4 million SEK (0.1). · Net profit for the period amounted to 5.1 million SEK (-0.2). · Earnings per share amounted to 0.13 SEK (-0.01). First half year in brief ·Net sales for the first half year amounted to 28.6 million SEK (26.5), which means a sales growth of 8 percent. ·Operating profit amounted to 0.8 million SEK (2.6). · Profit for the period amounted to 1.7 million SEK (2.5). · Earnings per

Statement from the Board of Directors of Semcon in response to Etteplan’s public takeover bid

Background This statement is made by the Board of Directors of Semcon AB (publ) (“Semcon” or the “Company") pursuant to section II.19 of Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). Etteplan Oyj (“Etteplan”) has today, on 23 August 2022, submitted a public cash takeover bid to the shareholders of Semcon to transfer all of their respective shares in Semcon to Etteplan (the “Offer”). According to the terms of the Offer, Etteplan offers a cash consideration of SEK 149 per share in Semcon (the “Offer Price”) corresponding to a total value of approximately SEK 2.7 billion[[1]].

OssDsign AB (publ) publishes Q2 2022 Interim Report

OssDsign AB (publ) announces that the interim report for Q2 2022 is now available as a pdf on the company's website www.ossdsign.com. A pdf version is also attached to this press release.For further information, please contact:Morten Henneveld, CEO, OssDsign ABTel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com Certified Adviser:Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se. About OssDsign:OssDsign is a developer and

My Life launches on Snapchat

New instant game produced by Nitro Games launches on the Snapchat platform Nitro Games has today announced that a new mobile game produced for Snapchat has been released. The game is called My Life and it’s available now for Snapchatters around the world. My Life is a casual sim-style game where players get to choose a career in anything from arts to medicine, earn money from their profession, and furnish their virtual apartments with trendy or quirky items. Players can visit each others’ virtual homes, and connect to create a neighborhood. My Life is an instant game, meaning

Modus Therapeutics publishes interim report for the second quarter 2022

STOCKHOLM, SWEDEN - 23 August 2022: Modus Therapeutics Holding AB (” Modus Therapeutics”) hereby publishes an interim report for the second quarter 2022. The report is available as an attached document and on the company's website (www.modustx.com/investors/financial-reports.html). Below is a summary of the interim reportThe second quarter in figures · The loss after tax amounted to TSEK 2 992 (2 533). · The loss per share amounted to SEK 0,19 (0,26). · The cash flow from current operations was negative in the amount of TSEK 3 228 (2 299). The first half-year in figures ·

Q2 Report – 30 June 2022

Flexion Mobile reports new growth record and hits USD 20 million revenue milestone for the quarter. Gross profit soars by 211% resulting in adjusted EBITDA[‡] of GBP 1.4 million.April-June 2022 performance · Total revenue increased by 127% to GBP 17.7m (7.8)* · Gross profit increased by 211% to GBP 2.9m (0.9) · Adjusted EBITDA[‡] increased to GBP 1.4m (0.02) · Operating result decreased to GBP -0.4m (-0.05) · Earnings per share amounted to GBP -1.42 pence  (-0.13 pence) · Cash and cash equivalents amounted to GBP 8.4m (15.6) January-June 2022 performance · Total

Alleima hosts its first Capital Markets Day

Alleima, formerly Sandvik Materials Technology, which is expected to be listed on Nasdaq Stockholm, today hosts its first Capital Markets Day, in Sandviken, Sweden. At the event, the executive management will present trends and characteristics of the Alleima markets, business, financial performance, and strategic direction. Alleima advances industries through materials technology. Alleima offers niched and premium products to a wide set of industries and has claimed strong market positions through its leading metallurgy expertise, global reach, and fully integrated value chain. The

Alleima hosts its first Capital Markets Day

Alleima, formerly Sandvik Materials Technology, which is expected to be listed on Nasdaq Stockholm, today hosts its first Capital Markets Day, in Sandviken, Sweden. At the event, the executive management will present trends and characteristics of the Alleima markets, business, financial performance, and strategic direction.Alleima advances industries through materials technology. Alleima offers niched and premium products to a wide set of industries and has claimed strong market positions through its leading metallurgy expertise, global reach, and fully integrated value chain. The

Bioretec’s ActivaPin™ bioresorbable implant provides good alternative treatment of pediatric elbow injuries

Bioretec Ltd          Press release          23 August 2022 at 9 a.m. EESTA recently published clinical study confirms the benefits of using fully bioresorbable ActivaPin™ implant together with bioabsorbable suture, for the tension band wire treatment of pediatric medial epicondyle humeral fractures. A tension band wire is a form of orthopaedic internal fixation method used to convert distraction forces into compression forces, promoting bone healing. The results of the retrospective cohort study shows that patients treated with bioresorbable ActivaPin™ were provided a good alternative

Calmark Sweden AB (publ) decides on the issue of units of approximately SEK 26.1 million with preferential rights for existing shareholders, subject to the subsequent approval of the general meeting

The board of directors of Calmark Sweden AB (publ) (“Calmark” or the “Company”) has today, conditioned by the Extraordinary General Meeting’s approval on September 22, 2022, decided on an issue of units consisting of shares and warrants with preferential rights for Calmark’s existing shareholders (“Rights issue”) of approximately SEK 26.1 million. The Rights Issue is covered by a maximum of 16,333,192 B shares and 4,083,298 warrants (units). The proceeds shall primarily finance sales and marketing efforts in connection with the commercialization of the Company’s products. About 80 percent of

Zwipe H1 2022 results – healthy commercial momentum

OSLO, NORWAY – 23 August 2022 – Zwipe AS ("Zwipe" or "the company") today announces its results for the first half 2022.   Operational highlights · Visa certifies Zwipe Pay Biometric Payment Card (“BPC”) Platform and issues Letter of Approval (“LoA”) to Zwipe.   · Beautiful Card Corporation (“BCC”), TAG Systems and Inkript obtain Visa LoAs for their own card built on the Zwipe Pay platform.   · Fraport AG, providing operational services to 31 airports globally, selected Zwipe Access as one of two solutions to test in a pilot of next generation access control

Interim report April-June 2022

Outcome April - June · Net sales amounted to  111 (492) kSEK · Profit after net financial items amounted to  -4 963 (-3 638) kSEK · Basic and diluted earnings per share -0,38 (-0,28) kSEK · Cash flow from operating activities and investing activities -5 576 (-1 678) kSEK Significant events April-June · Annual General Meeting was held in April. The AGM resolved on all points in accordance with the Board's and the Nomination Committee's proposals · A large university in the United Kingdom has purchased an Insplorion M8 instrument to expand on their cutting-edge

Green Landscaping Group strengthens its presence in Norway through acquisition of Braathen Landskapsentreprenør AS

23 August 2022 – 08:00 CEST Green Landscaping Group AB (publ) has signed an agreement to acquire Braathen Landskapsentreprenør AS with a turnover of approximately NOK 300 million.Braathen Landskapsentreprenør was founded in 1968 and is today one of Norway's largest landscaping companies. The company offers a complete range of services in landscaping, land construction, infrastructure and maintenance of outdoor environments. The company employs approximately 180 employees, has its headquarters in Ytre Enebakk and carries out work mainly in the Oslo region. - Braathen

Isofol Medical AB (publ) publishes interim report, January–June 2022

GOTHENBURG, Sweden, August 23, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–June 2022 is now available on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. Second quarter, April–June 2022 · Net revenue amounted to TSEK 4,027 (7,333) and other revenue to TSEK 0 (0) · The result for the period amounted to TSEK -54,033 (-45,394) · Earnings per share amounted to SEK -0.33 (-0.48) · Cash and cash equivalents at June 30 amounted to TSEK 277,727 (

Implantica publishes Interim Report Q2 2022

Executing on RefluxStop™ Commercialisation StrategySignificant events in the second quarter of 2022 · Implantica has completed the first AppetiteControl™ food sensor clinical trial on 20 human volunteers. The results are currently being evaluated. · Implantica successfully conducted its first User Meeting with 11 highly experienced anti-reflux Key Opinion Leaders (KOLs) participating, from several European countries. The purpose of the meeting was to standardize the surgical technique for the RefluxStop™ procedure. A consensus paper has been written and will be published. ·

Etteplan Oyj Announces a Recommended Cash Offer of SEK 149 per Share to the Shareholders of Semcon AB

ETTEPLAN OYJ, Stock Exchange Release, Inside information, 23 August 2022, 09.00 a.m. EEST THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER

There are no items matching the current filter
There are no more items matching the current filter
Back to top